How to cross-breed with dementia genetic and improve memory
Researchers have created the first genetic memory for Alzheimer’s disease using a single genetic mutation in a gene that is associated with a genetic cross-over in the form of the amyloid beta protein.
The findings could help researchers develop drugs that target the amyema protein, a form of inflammation that causes a buildup of amyloids in the brain, as well as other brain diseases, said Dr. Matthew Fuchs, an assistant professor of neurology at the University of Maryland School of Medicine.
Researchers at the Massachusetts General Hospital and the National Institutes of Health are developing a gene therapy for Alzheimers disease, which is the most common form of dementia.
In a report published in Science Translational Medicine, the researchers identified a specific variant of the gene that they said was responsible for the cross-reactivity in the new study.
The variant is located in the same gene as one that is known to cause Alzheimer’s, Fuchs said.
The researchers hope to study the genetic mutation and other brain changes that may lead to amylotriginemia, the inability to form amylots in the neurons that make up the brain.
In the future, the scientists hope to explore other ways to target the protein to control amylotic formation.
The study is a collaboration between the Massachusetts Genome Institute and the University at Buffalo, where Fuchs is a faculty member.
It was funded by grants from the National Institute of Neurological Disorders and Stroke, the National Science Foundation and the William and Flora Hewlett Foundation.
The work was supported by the Alzheimer’s Association, the American Association of Neurology, the Alzheimer Disease Association, and the Alzheimer Science Foundation.